Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: beta-Lactams; Lactams; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Vancomycin

Criteria

Inclusion Criteria:

• All patients admitted to or transferred to the SICU.

• Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU.

• Provide written informed consent

Exclusion Criteria:

• Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors.

• Females who are pregnant and breast feeding

• Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours.

• Those who have already been participating other clinical study related with antibiotics.